{"id":30029,"date":"2014-09-02T09:46:16","date_gmt":"2014-09-02T13:46:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=30029"},"modified":"2014-09-02T09:46:16","modified_gmt":"2014-09-02T13:46:16","slug":"primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029","title":{"rendered":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/02\/2014 (wallstreetpr) \u2013 Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by <strong>Boston Scientific Corporation (NYSE:BSX)<\/strong> recently. The company called this as the one-of-its-kind sham-controlled test based on a random basis and looking into <a href=\"http:\/\/www.benzinga.com\/pressreleases\/14\/08\/n4815708\/boston-scientific-announces-primary-endpoint-results-of-nectar-hf-clini\" target=\"_blank\"><strong>Vagus Nerve Stimulation<\/strong><\/a> (VNS) for the heart failure patients. The results were presented at the 2014 European Society of Cardiology Congress which took place in\u00a0Barcelona, Spain. European Heart Journal will soon publish the results as well.<\/p>\n<p style=\"text-align: justify;\"><strong>About the Study Involving NECTAR-HF Clinical Trial<\/strong><\/p>\n<p style=\"text-align: justify;\">In the study, 96 Class II-III patients of New York Heart Association (NYHA) suffering from ejection fraction of below 35% and heart failure were being evaluated. All these patients were asked to continue with their medical treatment, but at the same time, were randomized in the ratio of 2:1 to treatment or sham, respectively.<\/p>\n<p style=\"text-align: justify;\">Even though the quality of life metrics demonstrated a crucial symptomatic improvement, but there was a lack of any imperative effect on most important and less important endpoint measures associated with the cardiac remodelling as well as functional capacity of heart failure patients.<\/p>\n<p style=\"text-align: justify;\">After having received 6-months of randomization, the control patients start receiving active therapy. Thereafter, all patients go through 18 months for the safety endpoint.<\/p>\n<p style=\"text-align: justify;\"><strong>Statement from NECTAR-HF Principal Investigator<\/strong><\/p>\n<p style=\"text-align: justify;\">The NECTAR-HF Principal Investigator, Prof. <em>Zannad<\/em> said that the execution, as well as careful design of NECTAR-HF, led to the creation of high-quality data. He added that this will help in getting better understanding of role of VNS in HF patients\u2019 treatment.<\/p>\n<p style=\"text-align: justify;\">Prof. Zannad also added, \u201cNECTAR-HF should be the benchmark for future studies of novel device therapies\u201d that are involved in the treatment of heart failure.\u201d<\/p>\n<p style=\"text-align: justify;\"><strong>Statement from Rhythm Management for Boston Scientific<\/strong><\/p>\n<p style=\"text-align: justify;\">The Chief Medical Officer of Rhythm Management for Boston Scientific Corporation (NYSE:BSX), <em>Kenneth Stein<\/em>, M.D. in this context said that advancement of clinical studies, exploration of new therapies as well as provision of new diagnostic options for HF patients is the commitment of Boston Scientific Corporation (NYSE:BSX).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/02\/2014 (wallstreetpr) \u2013 Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by Boston Scientific [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":25594,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[2960,8584,1020,8585],"stock_ticker":[],"class_list":["post-30029","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-boston-scientific-corporation-nysebsx","tag-kenneth-stein","tag-nysebsx","tag-prof-zannad","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/02\/2014 (wallstreetpr) \u2013 Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by Boston Scientific [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-02T13:46:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"352\" \/>\n\t<meta property=\"og:image:height\" content=\"143\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\"},\"headline\":\"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)\",\"datePublished\":\"2014-09-02T13:46:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"keywords\":[\"Boston Scientific Corporation (NYSE:BSX)\",\"Kenneth Stein\",\"NYSE:BSX\",\"Prof. Zannad\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\",\"name\":\"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"datePublished\":\"2014-09-02T13:46:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg\",\"width\":352,\"height\":143},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"caption\":\"admin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029","og_locale":"en_US","og_type":"article","og_title":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR","og_description":"Boston, MA 09\/02\/2014 (wallstreetpr) \u2013 Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by Boston Scientific [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-02T13:46:16+00:00","og_image":[{"width":352,"height":143,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","type":"image\/jpeg"}],"author":"admin","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029"},"author":{"name":"admin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36"},"headline":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)","datePublished":"2014-09-02T13:46:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","keywords":["Boston Scientific Corporation (NYSE:BSX)","Kenneth Stein","NYSE:BSX","Prof. Zannad"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029","url":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029","name":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","datePublished":"2014-09-02T13:46:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Boston-Scientific-Corporation.jpg","width":352,"height":143},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/primary-endpoint-results-of-nectar-hf-clinical-trial-announced-by-boston-scientific-corporation-nysebsx-30029#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Primary Endpoint Results Of NECTAR-HF Clinical Trial Announced By Boston Scientific Corporation (NYSE:BSX)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","caption":"admin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=30029"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/25594"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=30029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=30029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=30029"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=30029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}